Form 8-K - Current report:
SEC Accession No. 0000950170-25-086246
Filing Date
2025-06-13
Accepted
2025-06-13 16:28:30
Documents
10
Period of Report
2025-06-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K acrv-20250613.htm   iXBRL 8-K 61397
  Complete submission text file 0000950170-25-086246.txt   174381

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20250613.xsd EX-101.SCH 26943
12 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20250613_htm.xml XML 5116
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 251047016
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)